Phase III study of adjuvant encorafenib plus binimetinib vs placebo in fully resected stage IIB/C BRAFV600-mutated melanoma: COLUMBUS-AD study design

ACJ Van Akkooi; A Hauschild; GV Long; M Mandala; M Kicinski; AS Govaerts; I Klauck; M Ouali; P Lorigan; AMM Eggermont

doi:10.1016/j.annonc.2022.10.494

Phase III study of adjuvant encorafenib plus binimetinib vs placebo in fully resected stage IIB/C BRAFV600-mutated melanoma: COLUMBUS-AD study design

ACJ Van Akkooi, A Hauschild, GV Long, M Mandala, M Kicinski, AS Govaerts, I Klauck, M Ouali, P Lorigan, AMM Eggermont

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Pages (from-to)	S1617-S1618
Number of pages	2
Journal	Annals of Oncology
Volume	33
DOIs	https://doi.org/10.1016/j.annonc.2022.10.494
Publication status	Published - Nov 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.annonc.2022.10.494

Cite this

Van Akkooi, ACJ., Hauschild, A., Long, GV., Mandala, M., Kicinski, M., Govaerts, AS., Klauck, I., Ouali, M., Lorigan, P., & Eggermont, AMM. (2022). Phase III study of adjuvant encorafenib plus binimetinib vs placebo in fully resected stage IIB/C BRAFV600-mutated melanoma: COLUMBUS-AD study design. Annals of Oncology, 33, S1617-S1618. https://doi.org/10.1016/j.annonc.2022.10.494

@article{deef87c0dd8d4fa4ba50935ab391161d,

title = "Phase III study of adjuvant encorafenib plus binimetinib vs placebo in fully resected stage IIB/C BRAFV600-mutated melanoma: COLUMBUS-AD study design",

author = "{Van Akkooi}, ACJ and A Hauschild and GV Long and M Mandala and M Kicinski and AS Govaerts and I Klauck and M Ouali and P Lorigan and AMM Eggermont",

year = "2022",

month = nov,

doi = "10.1016/j.annonc.2022.10.494",

language = "English",

volume = "33",

pages = "S1617--S1618",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier BV",

}

Van Akkooi, ACJ, Hauschild, A, Long, GV, Mandala, M, Kicinski, M, Govaerts, AS, Klauck, I, Ouali, M, Lorigan, P & Eggermont, AMM 2022, 'Phase III study of adjuvant encorafenib plus binimetinib vs placebo in fully resected stage IIB/C BRAFV600-mutated melanoma: COLUMBUS-AD study design', Annals of Oncology, vol. 33, pp. S1617-S1618. https://doi.org/10.1016/j.annonc.2022.10.494

TY - JOUR

T1 - Phase III study of adjuvant encorafenib plus binimetinib vs placebo in fully resected stage IIB/C BRAFV600-mutated melanoma

T2 - COLUMBUS-AD study design

AU - Van Akkooi, ACJ

AU - Hauschild, A

AU - Long, GV

AU - Mandala, M

AU - Kicinski, M

AU - Govaerts, AS

AU - Klauck, I

AU - Ouali, M

AU - Lorigan, P

AU - Eggermont, AMM

PY - 2022/11

Y1 - 2022/11

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=pure_starter&SrcAuth=WosAPI&KeyUT=WOS:000897943700465&DestLinkType=FullRecord&DestApp=WOS

U2 - 10.1016/j.annonc.2022.10.494

DO - 10.1016/j.annonc.2022.10.494

M3 - Meeting Abstract

SN - 0923-7534

VL - 33

SP - S1617-S1618

JO - Annals of Oncology

JF - Annals of Oncology

ER -

Phase III study of adjuvant encorafenib plus binimetinib vs placebo in fully resected stage IIB/C BRAFV600-mutated melanoma: COLUMBUS-AD study design

UN SDGs

Access to Document

Other files and links

Cite this